MannKind says it is in talks with partners for Afrezza MannKind says it is in talks with partners for Afrezza and the company sees needing 6 to 8 weeks post the drug's PDUFA date to finalize any partnerships, which it expects to be royalty based or profit sharing arrangments. MannKind sees pricing Affrezza comparable to injected insulin. MannKind notes that the PDUFA date for Afrezza is July 15. Comments made earlier by CFO Matthew Pfeffer at the Goldman Sachs Global Healthcare conference.
Stocks with call strike movement; MNKD SUNE MannKind (MNKD) November 4.5 call option implied volatility increased 3% to 81, SunEdison (SUNE) January 16 call option implied volatility decreased 1% to 73 according to IVolatility.